retatrutide clinical trial data Phase III study demonstrates 30% weight loss Retatrutide Phase 3: TRIUMPH Program

[1] [2] Because the drug is not yet licensed, all information regarding its side effects, including long-term risks, is derived from clinical trial data rather than post-marketing surveillance

We welcome self-referrals and will coordinate with your primary care physician as needed

Unlike currently approved weight loss medications, retatrutide works as a triple agonist, meaning it targets three different hormone receptors: GIP, GLP-1, and glucagon receptors

How Dr Edwin Ensures Safety During Weight Loss Treatment Dr Edwin and our doctors ensure that each patient receives ongoing supervision throughout their programme

Our guide on switching from tirzepatide to retatrutide covers the transition in detail

A glucagon-like Peptide-1 receptor agonist lowers weight by modulating the structure of gut microbiota